Supported Projects

Supported Approaches

PREVENT supports these approaches to prevention:

  • Immunoprevention (e.g., vaccines for cancers associated or not associated with infectious agents, immunomodulatory agents)
  • Chemoprevention (e.g., novel mechanisms, novel agents, anti-inflammatory approaches, drug repurposing, toxicity reduction strategies by dose and scheduling optimization, alternative routes of drug administration or combination regimens)
  • Clinically translatable biomarkers of tumor progression and/or prevention efficacy

PREVENT Cycles 1 through 16

A total of 95 projects have been implemented: 59 chemoprevention projects, 28 immunoprevention projects, and 8 biomarker projects.

Jump to:  Bladder | Breast | Cervical & Other HPV Cancers | Colon | Lung | Ovary | Pancreas | Prostate | Other Cancers | GMP Production

Cancer Type Type of Agent Project Title Project Number
Bladder Chemoprevention Evaluation of Agents/Protocols that Inhibit Two Major Pathways Involved in Human Urinary Bladder Cancer (PI3K, EGFR) and Protocols to Reduce Their Toxicity 261201500036I-0-26100002-1
Prevention of Urinary Bladder Cancer with Two "Clinically-Ready" Agents (Everolimus and Naproxen) When Administered in Combination 261201500036I-0-26100008-1
Preclinical Development of Newly Formulated Chemopreventive Agent 4-methylumbelliferone Prodrug 261201500036I-0-26100010-1
Evaluation of Two Different Classes of Compounds (STAT3 Inhibitors and SERMs) for Prevention of Urinary Bladder Cancers Pending
Immunoprevention Multi-antigen Vaccines for the Primary and Secondary Prevention of Bladder Cancer 261201500036I-0-26100006-1
Further Development of Multi-antigen Vaccines for the Primary and Secondary Prevention of Bladder Cancer 261201500036I-0-26100011-1
Breast Chemoprevention Evaluation of GLG-302, a STAT3 Antagonist, in the Prevention of Mammary Cancer 261201200021I-0-26100004-1
Efficacy of Metformin in the Methylnitrosourea-induced Model of ER+ Mammary Carcinogenesis when Animals are Placed on Different Diets: Standard Diet, High Fat Diet, and High Fructose Diet 261201200021I-0-26100005-1
Evaluation of the Prevention by ACTOPLUS/MET (Pioglitazone and Metformin) of ER+ and ER- Mammary Cancers Occurring in Rodents on a High-Fat Diet 261201200021I-0-26100006-1
Effect of Bazedoxifene Either Alone or in Combination with an Aromatase Inhibitor or Conjugated Estrogens (CE) in the Prevention of Mammary Cancers 261201200021I-0-26100007-1
Evaluation of the Cancer Prevention Efficacy of GLG-302 261201500036I-0-26100003-1
Support for Endoxifen Gel Clinical Development 261201500024I-0-26100002-1
Examination of HJC0152 as a Putative Modulator of Glucose and Energy Metabolism for Mammary Cancer 261201500018I-0-26100002-1
Targeted Casein Kinase 1d (CK1d) Inhibition as a Breast Cancer Prevention Strategy 261201500018I-0-26100005-1
Evaluation of "Clinical-Ready" Agents (Bazedoxifene and Lapatinib) in Combination for the Prevention of ER+ and ER- Mammary Cancers 261201500036I-0-26100005-1
Targeting the mTOR Pathway for the Prevention of Breast Cancer 261201500018I-0-26100006-1
Evaluation of STAT3 Antagonists in the Prevention of Mammary Cancer 261201500036I-0-26100007-1
Targeting the RXR Pathway for the Prevention of Triple Negative Breast Cancer 261201500018I-0-26100008-1
RANK Ligand Inhibition: A Potential Chemoprevention Strategy for Women at High Genetic Risk of Breast Cancer 261201500018I-0-26100009-1
Biomarker Chemopreventive Effects in Both Standard Chow Diets and High Fat Diets of Known Positive and Negative Chemopreventive Agents Employing Both High Risk (But Histologically Normal) Mammary Epithelium and Mammary Cancers Including Correlative Biomarkers N/A
Blood-based Biomarkers of Obesity-induced Breast Inflammation 261201200018I-0-26100003-1
Immunoprevention AAV1-Plac1 Vaccine Platform for Cancer Prevention 261201200018I-0-26100002-1
Efficacy of a Multi-antigen Vaccine in the Prevention of MNU-induced Mammary Cancers ER Positive in Female SD Rats 261201200021I-0-26100002-1
Development of a Multi-antigen, Multi-peptide Vaccine based on Gene Expression Information to Prevent Triple Negative Breast Cancer in a Mouse Model 261201500037I-0-26100007-1
Evaluating Whether a Concurrent Retinoid X Receptor Agonist Can Enhance the Efficacy of the HER2-IGFBP2-IGF1R Vaccine in Eliminating Existing Ductal Carcinoma In Situ and Preventing Progression of Invasive Breast Cancer 261201500036I-0-26100009-2
Further development of a Multi-antigen, Multi-peptide Vaccine Based on Gene Expression Information to Prevent Triple Negative Breast Cancer in a Mouse Model 261201500037I-0-26100008-1
Cancer Prevention by Vaccination Against Induced Antigens Pending
Cervical and Other HPV Cancers Chemoprevention Nonclinical Safety, Toxicokinetic, and Stability Evaluation of Bioresponse Diindolylmethane Vaginal Cream for Topical Treatment of Cervical Intraepithelial Neoplasia (CIN) 261201200025I-0-26100002-1
Immunoprevention Safety Evaluation of pNGVL4a-CRT-E6E7L2 (detox) Recombinant DNA Vaccine in Mice 261201200026I-0-26100002-1
Support for HPV16L1/RG1 Chimeric Virus-like Particle Vaccine Clinical Development 261201500026I-0-26100002-1
Colon Chemoprevention Preclinical Development of mPGES-1 and 5-LOX Selective Inhibitors for Chemoprevention 261201200020I-0-26100004-1
Efficacy of Aspirin and Naproxen (Short-term Frequent Dosing) in Colorectal Cancer Models 261201200020I-0-26100002-1
Combination of Aspirin and Omeprazole for Colorectal Cancer Chemoprevention 261201200020I-0-26100003-1
NSAID Chemoprevention in Colorectal Cancer 261201200020I-0-26100005-1
Efficacy of Eldecalcitol (ED-71) in Colorectal Cancer Prevention in ApcMin-FCCC/+Mouse Model 261201200015I-0-26100005-1
Prevention of Colorectal Cancer by ONC201 261201500038I-0-26100006-1
Combination of Aspirin or Naproxen with Omeprazole for Colorectal Cancer Chemoprevention with Clinically Relevant Doses 261201500038I-0-26100003-1
Determination of Dosing Regimens of Erlotinib in Combination with Sulindac for Prevention of Colorectal Cancer While Reducing Agent Toxicity 261201500018I-0-26100004-1
Chemoprevention of Colorectal Cancer with Olmesartan Medoxomil 261201500038I-0-26100011-2
A Novel Non-COX Inhibitory Sulindac Derivative for Colorectal Cancer Chemoprevention with Selective PDE10 and Wnt/b-Catenin Inhibitory Activity 261201500032I-0-26100003-1
LFA-9 (mPGES-1/5-LOX Inhibitor): Preclinical Investigational New Drug (IND)-directed GLP Toxicology Studies 261201500024I-0-26100005-1
Optimization of Dosing Regimens of Sulindac in Combination with Erlotinib for Small Intestinal and Colon Cancer Prevention Pending
TP-252: A Longer Acting Eicosapentaenoic Acid (EPA) Analogue for Colorectal Cancer Chemoprevention Pending
Biomarker Effect of a Chemopreventive Agent on the Fecal Metabolite Profile in Intestinal Neoplasia N/A
Molecular Heterogeneity of Inflammation and Growth Factor Pathways in Sporadic and Syndromic Colon Cancers: Implications for Prevention and Therapeutic Trials 261201200013I-0-26100008-1
Immunoprevention Characterization of Potential Antigens for Immunization Against Colon Cancer and Testing Multivalent Tumor Vaccines in Min Mice 261201200013I-0-26100003-1
Anti-Fusobacterium nucelatum Vaccine for Colorectal Cancer Immunoprevention 261201500039I-0-26100004-1
Testing of Combination Immuno- and Chemoprevention Strategies for Lynch Syndrome 261201500039I-0-26100003-1
Immunogenic effects of NSAIDs with and without a vaccine in colon cancer prevention 261201500036I-0-26100004-1
Frameshift Peptide Vaccine for the Prevention of Lynch Syndrome-associated Gastrointestinal Cancer 261201500039I-0-26100005-1
Further Development of Colovac, a Multi-antigen Multi-peptide Vaccine, for Colon Cancer Prevention Pending
Lung Chemoprevention In Vivo Evaluation of a Chemopreventive Agent, Ciclesonide, in Mouse Lung Tumor Model by Inhalation 261201200013I-0-26100002-1
Anti-inflammatory Effects of Fixed Dose Combination of Pioglitazone and Metformin for Lung Cancer Prevention 261201200015I-0-26100002-1
Effects of Weekly or Intermittent Dosing Regimens of EGFR, MEK and PI3K Inhibitors in Mouse Models of Lung Cancer 261201200013I-0-26100007-2
Lung Cancer Chemoprevention by microRNA Delivery 261201500037I-0-26100005-1
Chemoprevention with Aerosolized Bexarotene in Mouse Models of All Three Major Subtypes of Lung Cancer: Adenocarcinoma, Squamous Cell Carcinoma and Small Cell Lung Cancer 261201200020I-0-26100007-1
Support for Aerosol Development of Bexarotene 261201500024I-0-26100004-1
Chemoprevention with Aerosolized Let-7 microRNA in Mouse Models of Non-Small Cell Lung Cancer (Adenocarcinoma and Squamous Cell Carcinoma) Pending
Repurposing of the Macrolide Antibiotic Clarithromycin for the Prevention of Lung and Breast Cancer Pending
Biomarker Modulation of Cigarette Smoke-induced Alterations of microRNA Expression and Lung Tumors in Mice Treated with Aspirin and Naproxen 261201200015I-0-26100003-1
Effects of Chemopreventive Agents on Biomarkers Related to Lung Tumorigenesis: Alterations in "At Risk" Histogologically Normal Lung and Lung Lesions 261201200015I-0-26100004-1
Modulation of miRNA Expression in Blood or Other Biological Fluids Compared with Tissue Levels in Mice Exposed to Cigarette Smoke and/or with NSAIDs 261201200015I-0-26100006-1
Examination of Exosomal miRNAs as Potential Biomarkers for Chemopreventive Efficacy in Mouse Models of Lung Squamous Cell Carcinoma 261201500037I-0-26100003-1
Immunoprevention Use of TERT Vaccine in Prevention of Lung Cancer in Animal Models 261201200013I-0-26100006-1
Multi-antigen Vaccine for Lung Cancer Prevention 261201200013I-0-26100009-1
Development of Multiantigen Vaccines to Prevent the Development of Lung Adenocarcinomas Driven by either K-RAS or EGFR Oncoproteins in Mice 261201500037I-0-26100002-1
Rational Design and Development of a Multi-antigen Multi-peptide Vaccine Based on Genomic Information to Prevent Lung Cancer Initiation and Progression 261201500037I-0-26100004-1
Ovary Chemoprevention Ovarian Cancer Chemoprevention 261201500041I-0-26100002-1
Ovarian Cancer Chemoprevention 261201500038I-0-26100002-1
Immunoprevention Mesothelin Vaccination for the Prevention of Ovarian Cancer 261201200014I-0-26100002-1
Optimization and Further Development of Mesothelin Vaccine for the Prevention of Ovarian Cancer 261201500041I-0-26100003-1
Pancreas Chemoprevention Targeting P2X7 Receptor Antagonists for Prevention of Pancreatic Cancer 261201200013I-0-26100004-1
Targeting CCK2R for Pancreatic Cancer Prevention 261201200020I-0-26100006-1
Preclinical Studies to Evaluate the Combination of Metformin and Aspirin for the Prevention of Pancreatic Cancer 261201200013I-0-26100010-1
Optimization of GEM Models for High-Risk Cohorts of Human Pancreatic Cystadenomas, IPMNs and PanINs Progression to PDAC 261201500038I-0-26100004-1
Immunoprevention Development of Muc1 Vaccine for the Prevention of Pancreatic Cancer 261201200013I-0-26100005-1
Cancer Prevention by a-Enolase Vaccination 261201500018I-0-26100003-1
Effects of a Multipeptide KRAS Vaccine in the Prevention of Pancreatic Cancer Driven by KRAS Oncoprotein 261201500037I-0-26100006-1
Prostate Chemoprevention Chemoprevention of Prostate Cancer via Estrogen Receptor ß Agonists 261201200016I-0-26100003-1
Novel Androgen Receptor Antagonist-Mediated Chemoprevention of Prostate Cancer in Preclinical Model 261201500042I-0-26100002-1
Preclinical Evaluation of a New Lipid-based SMEDDS BR-9001 Formulation 261201500024I-0-26100003-1
Prostate Cancer Prevention by Aspirin and/or Other NSAIDs 261201500038I-0-26100005-1
Preclinical Development of Chemopreventive agent 4-methylumbelliferone  N/A
Preclinical Efficacy Evaluation of The Lipid-based SMEDDS Formulation of DIM, BR-9001 261201500042I-0-26100003-1
Other Cancers Chemoprevention Chemoprevention of endometrial hyperplasia and its transition to endometrial cancer with NSC 721689 261201500038I-0-26100008-1
Targeting the IL-6 Signaling Pathway as Chemopreventative Therapy for High-Risk Malignant Mesothelioma Populations 261201500032I-0-26100002-1
Oral Cancer Chemoprevention by Inhibitors of Inducible Nitric Oxide Synthase (iNOS) 261201200016I-0-26100002-1
Chemoprevention of Esophageal Cancer by Targeting Multiple Pathways in a Mouse Model of Barrett's Esophagus 261201500039I-0-26100002-1
Prevention of Hepatocellular Carcinoma (HCC) Associated with Non Alcoholic Steatohepatitis (NASH) 261201500018I-0-26100007-1
A Dual AKT/PDPK1 Inhibitor for Actinic Keratosis and Skin Cancer Prevention 261201500026I-0-26100003-1
Immunoprevention A Polyvalent Vaccine Against Fusion Proteins Observed in Solid Tumors 261201200018I-0-26100006-1
GMP Production Chemoprevention Large Scale Synthesis of 9-cis-UAB30 to Support Translational Development of this Novel Chemopreventive Rexinoid N/A
cGMP NSC 721689 Production for IRB-approved and NCI-funded Clinical Trials N/A
Immunoprevention cGMP Production of a Chimeric Virus-like Particle Vaccine (RG1-VLP) for Prevention of HPV-Associated Cancers N/A
Lowering the Risk of Lung and Other Cancers in High Risk Smokers using an Anti-nicotine Human mAb for Smoking Cessation N/A